OncoMatch/Clinical Trials/NCT05859074
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Is NCT05859074 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MQ719 and Pembrolizumab for cutaneous squamous cell carcinoma.
Treatment: MQ719 · Pembrolizumab — Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Melanoma
Sarcoma
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Allowed: BRAF mutation
Patients with BRAF-mutated melanoma should have received BRAF-targeted therapy.
Allowed: PD-L1 (CD274) expression <1
exception of patients with HNSCC with PD-L1 expression <1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: BRAF inhibitor — melanoma with BRAF mutation
Patients with BRAF-mutated melanoma should have received BRAF-targeted therapy.
Cannot have received: anti-PD-1 therapy
Exception: Patients who have failed prior anti-PD1/-PDL1 may be included. Washout of anti-PD1/-PDL1 at least 3 weeks prior to initiation of therapy in Part 1a and 2a. No washout period is required for Part 1b and 2b.
Prior non-immunotherapy, anti-tumor treatment including endocrine, chemical/radiotherapy, targeted therapy, or major surgery (but not anti-PD1/- L1 therapies) was discontinued for more than 4 weeks prior to enrollment
Lab requirements
Blood counts
coagulation function adequate (pt and aptt within x1.5 uln); platelets ≥ 75,000/mm^2; anc ≥ 1000/ul
Kidney function
cr <2 mg/dl
Liver function
serum bilirubin ≤1.5 x uln; ast and alt ≤2.5 uln (no liver mets); ast and alt ≤5.0 uln (for patients with liver mets)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify